Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials

References

• McKeeHDGuptaMSAhadMASaldanaMInnesJRFirst-choice treatment preferences for primary open-angle glaucoma in the United KingdomEye (Lond)200519892392415375365
   PubMed Web of Science ®Google Scholar
• van der ValkRWebersCALumleyTHendrikseFPrinsMHSchoutenJSA network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressureJ Clin Epidemiol200962121279128319716679
   PubMed Web of Science ®Google Scholar
• HommerAA review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertensionDrugs Today (Barc)201046640941620571609
   PubMed Web of Science ®Google Scholar
• European Glaucoma SocietyTerminology and Guidelines for Glaucoma2008 Available from: http://www.eugs.org/eng/EGS_guidelines.aspAccessed February 7, 2014
   Google Scholar
• LawSKSongBJFangECaprioliJFeasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance OrganizationOphthalmology2005112122123213016225924
   PubMed Web of Science ®Google Scholar
• ColemanALEvidence-based management of glaucoma: recommendations of an expert panelGlaucoma Disease Management Guide PDR1st edMontvale, NJ, USAThomson PDR2004
   Google Scholar
• AptelFCucheratMDenisPEfficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trialsJ Glaucoma200817866767319092464
   PubMed Web of Science ®Google Scholar
• KymesSMBurkCFeinmanTWilliamsJMHollanderDADemonstration of an online tool to assist managed care formulary evidence-based decision making: meta-analysis of topical prostaglandin analog efficacyTher Clin Risk Manag2011728329021845051
   PubMed Web of Science ®Google Scholar
• KatzLJCohenJSBatoosinghALFelixCShuVSchiffmanRMTwelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertensionAm J Ophthalmol20101494661671. e66120346780
   PubMed Web of Science ®Google Scholar
• AllerganA Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular HypertensionClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated October 7, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT01525173. NLM identifier: NCT01525173Accessed March 3, 2014
   Google Scholar
• AllerganComparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®ClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated December 7, 2011]. Available from http://clinicaltrials.gov/ct2/show/NCT01170884?term=NCT01170884&rank=1. NLM identifier: NCT01170884Accessed March 3, 2014
   Google Scholar
• American Academy of OphthalmologyPrimary Open-Angle Glaucoma. Preferred Practice GuidelinesSan Francisco, CAAmerican Academy of Ophthalmology2010
   Google Scholar
• WilliamsRDEfficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprostAdv Ther200219627528112665048
   PubMed Web of Science ®Google Scholar
• GandolfiSACiminoLEffect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprostOphthalmology2003110360961412623831
   PubMed Web of Science ®Google Scholar
• BourniasTELeeDGrossRMattoxCOcular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertensionJ Ocul Pharmacol Ther200319319320312828838
   PubMed Web of Science ®Google Scholar
• KammerJAKatzmanBAckermanSLHollanderDAEfficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre studyBr J Ophthalmol2010941747919726422
   PubMed Web of Science ®Google Scholar
• HigginbothamEJSchumanJSGoldbergIOne-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertensionArch Ophthalmol2002120101286129312365906
   PubMed Web of Science ®Google Scholar
• CrichtonACVoldSWilliamsJMHollanderDAOcular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertensionAdv Ther201330326027023475405
   PubMed Web of Science ®Google Scholar
• KurtzSMannOIncidence of hyperemia associated with bimatoprost treatment in naive subjects and in subjects previously treated with latanoprostEur J Ophthalmol200919340040319396785
   PubMed Web of Science ®Google Scholar
• CrichtonACNixonDRSimonyiSAn observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan RC Early Analysis Review (CLEAR) trialClin Ophthalmol201371823277737
   PubMedGoogle Scholar
• NixonDRSimonyiSBhogalMAn observational study of bimatoprost 0.01% in treatment-naive patients with primary open angle glaucoma or ocular hypertension: the CLEAR trialClin Ophthalmol201262097210323269858
   PubMedGoogle Scholar
• WhitsonJTGlaucoma: a review of adjunctive therapy and new management strategiesExpert Opin Pharmacother20078183237324918035966
   PubMed Web of Science ®Google Scholar
• RossettiLGandolfiSTraversoCAn evaluation of the rate of nonresponders to latanoprost therapyJ Glaucoma200615323824316778647
   PubMed Web of Science ®Google Scholar
• SakuraiMHigashideTTakahashiMSugiyamaKAssociation between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprostOphthalmology200711461039104517467803
   PubMed Web of Science ®Google Scholar
• StewartWCDayDGSharpeEDDubinerHBHolmesKTStewartJAEfficacy and safety of timolol solution once daily vs timolol gel added to latanoprostAm J Ophthalmol1999128669269610612504
   PubMed Web of Science ®Google Scholar